Data on BAY 43-9006 at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial: Abstract No: 4501

Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma: Abstract No: 7507

A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome or acute myeloid leukemia: A National Cancer Institute of Cancer Clinical Trials Group Study: Abstract No: 6611

A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer: Abstract No: 3059

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors: Abstract No: 3049

Novel methodology of response assessment in hepatocellular carcinoma – Assessing response by change in tumor enhancement in distinction from conventional means: Abstract No: 3107

Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors: Abstract No: 3056

Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension: Abstract No: 2035

BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience: Abstract No: 7506

ASCO Homepage: www.asco.org


Clinical trials information: www.clinicaltrials.gov


American Cancer Society: www.cancer.org


Information on renal cell cancer: www.kidneycancerassociation.org


Information on melanoma: www.melanomainternational.org